Eli Lilly Launches 'Once-A-Week' Weight Loss Drug 'Mounjaro' To Tackle Obesity & Diabetes In India

MNC pharma major, Eli Lilly and Company said it has launched a first-of-its-kind medication for obesity and type 2 diabetes in India after obtaining approval from the Central Drugs Standard Control Organisation (CDSCO).

What is Mounjaro?

The company introduced Mounjaro (tirzepatide), a weekly injection for obesity and type 2 diabetes in a single-dose vial presentation following the marketing authorisation from the CDSCO.

It is a first-of-its-kind treatment for obesity, overweight, and type 2 diabetes that activates GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) hormone receptors.

Mounjaro is indicated as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with an initial body mass index (BMI) of 30 kg/m2 or greater (obesity) or 27 kg/m2 or greater (overweight) in the presence of at least one weight-related comorbid condition.

It is also indicated as an adjunct to diet and exercise to enhance glycemic control in adults with type 2 diabetes mellitus.

Mounjaro activates both GIP and GLP-1 hormone receptors, causing significant weight loss and blood sugar control in clinical trials. GLP-1, or glucagon-like peptide-1, are hormones produced in the human body that are crucial in regulating blood sugar levels and appetite.

“The dual burden of obesity and type 2 diabetes is rapidly emerging as a major public health challenge in India,” said Winselow Tucker, President and General Manager, of Lilly India, adding that the company is “committed to collaborating with the government and industry to improve prevention and management.”

Mounjaro in India will be “offering a new approach to metabolic health management,” said Dr. Manish Mistry, Senior Medical Director, Lilly India.

The medication works by selectively binding and activating GIP and GLP-1 receptors, improving insulin secretion, reducing glucagon levels, enhancing insulin sensitivity, and delaying gastric emptying.

Incidentally, Mounjaro also influences appetite regulation, fat mass reduction, and lipid utilization in the body.

Also read: 'Bengaluru Is Dirty': South Indian Employee ‘Regrets’ Moving Out Of Noida For Rs 30K Hike (startuppedia.in)